

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

---

**FORM 8-K**

---

**CURRENT REPORT  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934**

Date of Report (Data of earliest event reported): **May 20, 2022**

---

**X4 PHARMACEUTICALS, INC.**

(Exact name of registrant as specified in its charter)

---

**Delaware**  
(State or other jurisdiction of incorporation)

**001-38295**  
(Commission File Number)

**27-3181608**  
(IRS Employer Identification No.)

**61 North Beacon Street, 4th Floor**  
**Boston, Massachusetts**  
(Address of principal executive offices)

**02134**  
(Zip Code)

**(857) 529-8300**  
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value \$0.001 per share	XFOR	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act

---

---

**Item 7.01 Regulation FD Disclosure.**

On May 20, 2022, X4 Pharmaceuticals, Inc. (the “Company”) posted an updated corporate presentation on the Company’s website. To access the presentation, investors should visit the “Investors” section of the Company’s website at [www.x4pharma.com](http://www.x4pharma.com).

The information furnished under this Item 7.01 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

**Item 8.01 Other Events.**

The Company updated its corporate presentation to reflect the following information, which has been disclosed in the Company’s quarterly report on Form 10-Q for the period ended March 31, 2022 filed with the Securities and Exchange Commission on May 12, 2022:

- top-line data from global Phase 3 clinical trial of mavorixafor (4WHIM trial) expected in 4Q 2022;
  - interim data from Phase 1b clinical trial in chronic neutropenia expected in 3Q 2022;
  - additional data from Phase 1b clinical trial in Waldenström’s Macroglobulinemia (lymphoma) expected in 2H 2022;
  - investigational new drug (IND) application of X4P-002 expected to be filed with the U.S. Food and Drug Administration in 4Q 2022; and
  - estimated prevalence of Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM).
-

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934 the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**X4 PHARMACEUTICALS, INC.**

Date: May 20, 2022

By: /s/ Derek Meisner  
Derek Meisner  
Chief Legal Officer